The Clinical Usefulness of Nuclear Matrix Protein-22 in Patients with End-Stage Renal Disease and Microscopic Hematuria

Figures & data

Table 1.  Patient characteristics I—baseline demographics of evaluable patients (n = 57).

Characteristics	No. of patients (%) or test value (%)
Median age, year (range)	50 (20–75)
Male/female	34/23 (59.6%/40.4%)
Median body mass index (range)	28.3 (18.7–44.3)
Median serum creatinine, mg/dL (range)	6.55 (2.1–21.1)
Medium glomerular filtration rate (mL/min/1.73 m^2) (range)	8.1 (2.53–31.03)
Medium proteinuria, mg/dL (range)	256.5 (0–750)
NMP22 test results
Positive	19 (33.3%)
Negative	38 (66.7%)
Positive NMP22 test results (M/F ratio)
Positive	11/8 (19.3%/14.0%)
Negative	22/16 (38.6%/28.1%)
Urine cytology results (Patients with positive NMP 22 test)
Normal	16 (84.2%)
Atypia	3 (15.8%)
Cancer cells present	0 (0 %)
Urine cytology results (patients with negative NMP 22 test)
Normal	33 (86.8%)
Atypia	5 (13.2%)
Cancer cells present	0 (0%)
Median urine output in mL per 24 h (range)	591.5 (118.3–1656.2)
Type of dialysis performed
None	14 (24.6%)
Peritoneal dialysis	11 (19.3%)
Hemodialysis	32 (56.1%)

Table 2.  Patient characteristics II—causes of end-stage renal disease.

Cause	No. of patients (%)
Diabetes mellitus	4 (7%)
Arterial hypertension	8 (14%)
Diabetes mellitus and arterial hypertension	30 (52.6%)
Prune-belly-syndrome	1 (1.75%)
Glomerulonephritis	4 (7 %)
Lithium-treatment-induced	1 (1.75%)
Lupus-nephritis	2 (3.5%)
Adult polycystic chronic kidney disease	3 (5.3%)
IgA-nephropathy	2 (3.5%)
Wegener’s disease	1 (1.75%)
Chronic pyelonephritis	1 (1.75%)

Table 3.  Urinary bladder biopsy results (n = 21).

Histopathological results	No. of patients (%)
Patients with positive NMP22 test (n = 16)
Normal bladder urothelium	8 (50.0%)
Chronic cystitis	7 (43.7%)
Transitional cell cancer	1 (6.3%)
Patients with only positive urine cytology (n = 3)
Normal bladder urothelium	2 (66.7%)
Chronic cystitis	1 (33.3%)
Patients with positive NMP22 test and positive urine cytology (n = 3)
Normal bladder urothelium	1 (33.3%)
Chronic cystitis	2 (66.7%)
Patients with positive NMP22 test or urine cytology and abnormal urethrocystoscopy (n = 6)
Normal bladder urothelium	1 (16.7%)
Chronic cystitis	4 (66.6%)
Transitional cell cancer	1 (16.7%)
Patients with negative NMP22 test/negative urine cytology but abnormal urethrocystoscopy (n = 2)
Normal bladder urothelium	1 (50%)
Chronic cystitis	0 (0%)
Transitional cell cancer	1 (50%)

Table 4.  NMP22 test sensitivity, specificity, and negative and positive predictive values.

	% Sensitivity	% Specificity	% Positive predictive value	% Negative predictive value
NMP22 test	50	67.2	52.6	97.3